Выводы. Технологии регенеративной медицины имеют перспективы в широком спектре областей,
может стать новым рубежом для трансплантационной медицины, которая будет отвечать за будущее наук о
здоровье.
Литература 1.
Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Castro S et al. OPTN/SRTR 2017 annual data report:
kidney. Am J Transplant 2019; 19: 19–123.
2.
Asch DA, Volpp KG. Reimagining halfway technologies with behavioral science. Ann Intern Med 2017; 167: 505–
506.
3.
Bozek DN, Dunn TB, Kuhr CS, et al. Complete chain of the first global kidney exchange transplant and 3-yr follow-
up. Eur Urol Focus 2018; 4: 190–197.
4.
Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N
Engl J Med 2016; 374: 940–950.
5.
Orlando G, Murphy SV, Bussolati B, et al. Rethinking regenerative medicine from a transplant perspective (and vice
versa). Transplantation 2019; 103: 237–249.
6.
Kang HW, Lee SJ, Ko IK, Kengla C, Yoo JJ, Atala A. A 3D bioprinting system to produce human-scale tissue
constructs with structural integrity. Nat Biotechnol 2016; 34: 312–319.
7.
Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G et al. Charting cellular identity during human in
vitro β-cell differentiation. Nature 2019; 569: 368–373.
8.
Yamaguchi T, Sato H, Kato-Itoh M, Goto T, Hara H, Sanbo M et al. Interspecies organogenesis generates
autologous functional islets. Nature 2017; 542: 191–196.
9.
Smith AM, Maguire-Nguyen KK, Rando TA, Zasloff MA, Strange KB, Yin VP. The protein tyrosine phosphatase
1B inhibitor MSI-1436 stimulates regeneration of heart and multiple other tissues. NPJ. Regenerat Med. 2017; 2: 4.